UY28340A1 - Profármaco inhibidor de beta-lactamasa - Google Patents

Profármaco inhibidor de beta-lactamasa

Info

Publication number
UY28340A1
UY28340A1 UY28340A UY28340A UY28340A1 UY 28340 A1 UY28340 A1 UY 28340A1 UY 28340 A UY28340 A UY 28340A UY 28340 A UY28340 A UY 28340A UY 28340 A1 UY28340 A1 UY 28340A1
Authority
UY
Uruguay
Prior art keywords
beta
mammals
profármaco
lactamasa
inhibitor
Prior art date
Application number
UY28340A
Other languages
English (en)
Inventor
Dale Gordon Mcleod
Anthony Marfat
John Paul O Donnell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28340A1 publication Critical patent/UY28340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/861—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a hydrocarbon radical or a substituted hydrocarbon radical, directly attached in position 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Profármacos de sulfona del ácido 6-B-hidroximetilpenicilánico que tienen la estructura Como se definió en la memoria y reivindicaciciones, y sus solvatos,. Composiciones farmacéuticas comprendiendo profármaco referido sus solvatos, un antibiótico beta-lactama opcional y al menos un vehículo farmacéuticamente aceptable. Procedimiento para aumentar eficacia terapéutica de antibiótico betalactama en mamífero mediante adminstración de cantidad eficaz de antibiótico beta-lactama y cantidad que aumenta la eficacia de un profármaco de la presente, o un solvato del mismo. Procedimiento para tratar infección bacteriana en mamífero mediante aadministración de cantidad teraéuticamente eficaz de composición farmacéutica de la presente a mamífero necesitsdo de ello.
UY28340A 2003-06-05 2004-06-02 Profármaco inhibidor de beta-lactamasa UY28340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47645603P 2003-06-05 2003-06-05
US49842203P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
UY28340A1 true UY28340A1 (es) 2005-01-31

Family

ID=33514083

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28340A UY28340A1 (es) 2003-06-05 2004-06-02 Profármaco inhibidor de beta-lactamasa

Country Status (14)

Country Link
US (1) US20050004093A1 (es)
EP (1) EP1636240A1 (es)
JP (1) JP2006526612A (es)
AR (1) AR044482A1 (es)
BR (1) BRPI0410936A (es)
CA (1) CA2528065A1 (es)
CL (1) CL2004001343A1 (es)
MX (1) MXPA05012895A (es)
NL (1) NL1026340C2 (es)
PA (1) PA8604001A1 (es)
PE (1) PE20050629A1 (es)
TW (1) TW200504010A (es)
UY (1) UY28340A1 (es)
WO (1) WO2004108733A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
EP1551558A1 (de) 2002-10-14 2005-07-13 H. Börger & Co. GmbH Verfahren und vorrichtung zum fürdern von pulverfürmigem material
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE34011B1 (en) * 1969-03-13 1975-01-08 Leo Pharm Prod Ltd New penicillin esters
IE34019B1 (en) * 1969-03-18 1975-01-08 Leo Pharm Prod Ltd New semi-synthetic penicillin esters
US3957764A (en) * 1969-11-11 1976-05-18 Lovens Kemiske Fabrik Produktionsaktieselskab 6-aminopenicillanic acid derivatives
US3862181A (en) * 1970-10-28 1975-01-21 Squibb & Sons Inc Process for preparing cephalosporins
US4397783A (en) * 1979-03-05 1983-08-09 Pfizer Inc. Process for converting 6,6-disubstituted penicillanic acid derivatives to the 6-β-congeners
US4287181A (en) * 1979-10-22 1981-09-01 Pfizer Inc. Derivatives of 6β-hydroxyalkylpenicillanic acids as β-lactamase inhibitors
US4432970A (en) * 1979-11-23 1984-02-21 Pfizer Inc. 6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors
GB2076812A (en) * 1980-05-22 1981-12-09 Ciba Geigy Ag Penam-dioxide compounds, processes for their manufacture, and their use
AU559689B2 (en) * 1981-09-22 1987-03-19 Kureha Kagaku Kogyo K.K. Penicillin derivative
US4406887A (en) * 1981-10-13 1983-09-27 Bristol-Myers Company Method for treating resistant bacteria including anaerobes
US4377590A (en) * 1982-05-10 1983-03-22 Pfizer Inc. Derivatives of ampicillin and amoxicillin with beta-lactamase inhibitors
US4428935A (en) * 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
US4826833A (en) * 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
US4521533A (en) * 1984-07-12 1985-06-04 Pfizer Inc. Salts of 6-alpha-(aminomethyl)penicillanic acid 1,1-dioxide esters and beta-lactam antibiotics
US4762921A (en) * 1985-04-18 1988-08-09 Pfizer Inc. 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives
US5200403A (en) * 1987-07-10 1993-04-06 Farmitalia Carlo Erba S.R.L. Inhibition of βlactamase with 6 β-(substituted methyl)-penicillanic acid derivatives
JPH03206038A (ja) * 1990-01-08 1991-09-09 Yoshitomi Pharmaceut Ind Ltd 抗菌剤
GB9001405D0 (en) * 1990-01-22 1990-03-21 Leo Pharm Prod Ltd New intermediates,their production and use
KR0178957B1 (ko) * 1990-08-20 1999-03-20 도리이 신이치로 페넴 화합물
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
JP3866298B2 (ja) * 1997-12-29 2007-01-10 リサーチ コーポレイション テクノロジーズ，インコーポレイティド β−ラクタマーゼインヒビターとしての２β−置換化−６−アルキリデンペニシラン酸誘導体
ATE288438T1 (de) * 1999-03-03 2005-02-15 Astur Pharma Sa Verfahren zur herstellung von dioxopenicillansäurederivaten
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa

Also Published As

Publication number Publication date
JP2006526612A (ja) 2006-11-24
NL1026340A1 (nl) 2004-12-07
TW200504010A (en) 2005-02-01
NL1026340C2 (nl) 2005-09-14
US20050004093A1 (en) 2005-01-06
CL2004001343A1 (es) 2005-04-22
WO2004108733A1 (en) 2004-12-16
EP1636240A1 (en) 2006-03-22
BRPI0410936A (pt) 2006-06-27
MXPA05012895A (es) 2006-02-22
PA8604001A1 (es) 2004-12-16
CA2528065A1 (en) 2004-12-16
PE20050629A1 (es) 2005-08-25
AR044482A1 (es) 2005-09-14

Similar Documents

Publication Publication Date Title
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
WO2006018182A8 (en) Combinations for the treatment of diseases involving cell proliferation
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
PA8489501A1 (es) Antibioticos cetolidos
AR060089A1 (es) Tratamiento del dolor
BRPI0506493A (pt) combinações terapêuticas
ECSP055625A (es) Profarmaco inhibidor de beta-lactamasa
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
AR074309A1 (es) Compuestos anti-inflamatorios y sus composiciones farmaceuticas, dentifricas y adhesivas. metodo
BRPI0607701A2 (pt) composto ou um sal, éster, solvato, estereoisÈmero, tautÈmero ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade antibacterialmente eficaz de um composto junto com um veìculo farmaceuticamente aceitável, e, método de preparação de um composto
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
BR112022001344A2 (pt) Combinações de antibióticos beta-lactâmicos administrados por via oral e derivados de avibactam para tratamento de infecções bacterianas
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
PT1109560E (pt) Compostos uteis como inidores de aicarft
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
UY28340A1 (es) Profármaco inhibidor de beta-lactamasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150522